Cargando…

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with surgery alone. However, since 2011, there has been an important revolution in the treatment of melanoma with new effective treatments. Targeted therapy and immunotherapy with checkpoint inhibitors have changed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222774/ https://www.ncbi.nlm.nih.gov/pubmed/34178657 http://dx.doi.org/10.3389/fonc.2021.670726

Ejemplares similares

Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
por: Ascierto, Maria Libera, et al.
Publicado: (2015)

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
por: Trojaniello, Claudia, et al.
Publicado: (2023)

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management
por: Simeone, Ester, et al.
Publicado: (2019)

Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2021)

Editorial: Combination Strategies in the Treatment of Melanoma
por: Ascierto, Paolo Antonio
Publicado: (2016)

How we treat locoregional melanoma
por: Troiani, T., et al.
Publicado: (2021)

Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience
por: Crispo, Anna, et al.
Publicado: (2021)

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets
por: Basile, Maria Sofia, et al.
Publicado: (2019)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Editorial: The role of immunotherapy in melanomas
por: Fateeva, Anna, et al.
Publicado: (2023)

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
por: Mannavola, Francesco, et al.
Publicado: (2020)

Neuropilin-1 as Therapeutic Target for Malignant Melanoma
por: Graziani, Grazia, et al.
Publicado: (2015)

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
por: Palmieri, Giuseppe, et al.
Publicado: (2015)

YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
por: Kwiatkowska, Dominika, et al.
Publicado: (2022)

Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies
por: Zhu, Haipeng, et al.
Publicado: (2021)

The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review
por: Odiase, Otasowie, et al.
Publicado: (2021)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

Immunotherapy in non-melanoma skin cancer: updates and new perspectives
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

The immunotherapy advancement targeting malignant blastomas in early childhood
por: Zang, Bolun, et al.
Publicado: (2023)

Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas
por: Ottaviano, Margaret, et al.
Publicado: (2022)

MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes
por: Shteinman, Eva R., et al.
Publicado: (2022)

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study
por: Marconcini, Riccardo, et al.
Publicado: (2022)

Targeted Therapy; From Advanced Melanoma to the Adjuvant Setting
por: Ahn, Antonio, et al.
Publicado: (2013)

Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis
por: Gallenga, Carla Enrica, et al.
Publicado: (2022)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma
por: Hodi, F. Stephen, et al.
Publicado: (2021)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
por: Cheng, Yuan, et al.
Publicado: (2021)

Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity
por: Yang, Xiao-Guang, et al.
Publicado: (2019)

Advances in targeted therapy and immunotherapy for melanoma (Review)
por: Qin, Ziyao, et al.
Publicado: (2023)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
por: Thornton, Jessica, et al.
Publicado: (2022)

Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers
por: Guida, Michele, et al.
Publicado: (2022)

Research landscape and trends of melanoma immunotherapy: A bibliometric analysis
por: Liu, Yanhao, et al.
Publicado: (2023)

CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment
por: Zhou, Xuezhi, et al.
Publicado: (2021)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tog9enbrlmpnbjrs8u7m8b7eh2